Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
{{output}}
Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in malignancies associated with germline BRCA1 or BRCA2 pathogenic variants, such as breast, ovarian, prostate, and pancreatic cancer. In malignancies not associated with germline BRCA1 or BRCA2... ...
